Holen Sie sich die Stockscreener-App
526.19
0.73%
3.81
Handel nachbörslich:
527.40
1.21
+0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
Innovation Is Driving a New Bull Market in Biotech. 16 Ways to Play It, From Our Roundtable Experts. - Barron's
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Vertex Pharmaceuticals stock tracks kidney pipeline progress - AD HOC NEWS
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - fortune.com
BMO Capital Remains a Buy on Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Vertex Pharmaceuticals (VRTX) Gets a Hold from Canaccord Genuity - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Roivant Sciences (ROIV) - The Globe and Mail
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues - Yahoo Finance
Vertex Pharma options analysis: heavy put activity signals near-term caution - Investing.com
Allstate, Autozone, Vertex Pharmaceuticals - TradingView
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Vertex Pharmaceuticals Incorporated (VRTX) Options ChainYahoo Finance - Yahoo! Finance Canada
Vertex Pharmaceuticals (VRTX) Q2 2026 Earnings Call Transcript - fortune.com
Vertex reports positive Phase IIb data as it completes enrollment in pivotal AMKD trial - The Pharma Letter
Autologous Hematopoietic Stem Cell Gene Therapy Market - GlobeNewswire
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race - Yahoo Finance
Jefferies raises Vertex stock price target on kidney drug data By Investing.com - Investing.com Canada
Vertex reports results from Phase IIb AMPLIFIED trial for AMKD - Clinical Trials Arena
TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating - Yahoo Finance
What could reshape the outlook for Vertex Pharmaceuticals (NASDAQ:VRTX) now? - Kalkine Media
Vertex Pharma stock gains 3 percent ahead of the open - AD HOC NEWS
The Surprise That Sent Vertex — And Its Chief Rival — Soaring - Investor's Business Daily
Vertex Kidney Pill Shows Broader Promise, Lifting Rival Maze 25% - finance.biggo.com
Vertex Pharmaceuticals Stock Gains On Kidney Drug DataVertex Pharmaceuticals (NASDAQ:VRTX) - Benzinga
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder - Yahoo Finance
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech - Barron's
BMO reiterates Vertex stock rating on positive trial data By Investing.com - Investing.com Canada
Vertex Pharmaceuticals stock gains as inaxaplin data advance - AD HOC NEWS
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial - BioSpace
Vertex’s midstage data amplify kidney disease market opportunity - Fierce Biotech
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria - TradingView
Urine protein fell 42.7% in a kidney trial. Vertex finished enrolling its next study. - Stock Titan
Inside the Vertex Pharmaceuticals (VRTX) Story Reshaping Healthcare Stocks Sentiment - Kalkine Media
Vertex Pharma stock slips 1.55 percent pre-market before the open - ad-hoc-news.de
Vertex Pharmaceuticals (VRTX) Stock Analysis: A Biotech Powerhouse with 11.97% Potential Upside - DirectorsTalk Interviews
Fierce Biotech Layoff Tracker 2026: Novo reveals 4k more employees were laid off; Sionna halves staff - Fierce Biotech
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Is This Biotech Stock Too Cheap to Ignore After Its Latest Pullback? - The Motley Fool
2 Reasons to Like VRTX (and 1 Not So Much) - Yahoo Finance
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Vertex Pharmaceuticals (VRTX), Why Is It Getting Fresh Attention Now? - Yahoo Finance
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX - Business Wire
Vertex Pharmaceuticals Eyes Renal Growth With Key PDUFA, Pipeline Catalysts Ahead - TradingView
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
DC Circuit Agrees Vertex Pharmaceuticals’ Fertility Support Program Would Violate Anti-Kickback Statute - ArentFox Schiff
Vertex Pharmaceuticals Inc Share PriceVRTX, RNS News, Articles, Quotes, & Charts (NASDAQ:VRTX) - Proactive financial news
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis - TradingView
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis - Yahoo Finance
Vertex Pharma stock gains analyst support as JPMorgan raises price target - ad-hoc-news.de
VRTX Reinstated by JP Morgan -- Price Target Raised to $560 - GuruFocus
Vertex trades higher after JPM gives bullish rating - TradingView
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher - FXEmpire
Executives On The Move: Vertex Expands Its Leadership Team Following Crinetics Acquisition - insights.citeline.com
1.00%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):